UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products. UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does UnicoCell Biomed Co., Ltd. (6794) operate in?
UnicoCell Biomed Co., Ltd. belongs to the Other sector and operates in the Biotechnology industry.
What is UnicoCell Biomed Co., Ltd. (6794) current stock price?
As of the latest data, UnicoCell Biomed Co., Ltd. stock price is NT$71.20, with a previous close of NT$71.20.
What is UnicoCell Biomed Co., Ltd. (6794) current market capitalization?
UnicoCell Biomed Co., Ltd. market cap is approximately 4.53 billion.
What is UnicoCell Biomed Co., Ltd. (6794) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.89.
Does UnicoCell Biomed Co., Ltd. (6794) pay dividends?
No. UnicoCell Biomed Co., Ltd. does not pay a dividend.
What is UnicoCell Biomed Co., Ltd. (6794) beta (volatility) score?
UnicoCell Biomed Co., Ltd. has a beta of -0.229, indicating lower volatility than the overall market.
